Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors

• Published in: Journal of clinical oncology Vol. 39; no. 15_suppl; p. 1024
• Main Authors: Hu, Xichun, Zhang, Jian, Liu, Rujiao, Gao, Shuiping, Qing, Yan, Yi, Shuli, Yuan, Juanjuan, Chen, Hong, Fan, Bin, Zheng, Haochuan, Wang, Jingyi
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer Health 20.05.2021

1024Background: A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (transtuzumab) via a stable protease-cleavable valine citrulline linker. In a phase I trial in US patients (pts) with relapsed o...